Sumitomo Pharma (TSE:4506) Stock Looks Cheap Beyond One Off Fueled Margins

Sumitomo Pharma just posted one of those quarters that makes the recent share price slide look out of sync. The stock closed at ¥1,248 on 31 July, capping a 30 day decline of about 16%, yet Q1 FY2027 landed with solid revenue of ¥129,495m and basic earnings per share of ¥39.02.

The headline is profitability. Net income from continuing operations came in at ¥16,997m for the quarter. That sits on top of a trailing net margin of 23.7% and a P/E around 5x, which still prices the stock as if the earnings story has not turned.

Love Sumitomo Pharma's strong margin and low P/E but unsure if you want more companies with similar earnings power on your radar? Check out our hand picked 64 high quality undiscovered gems for stocks that combine established profitability with underappreciated valuations.

Q1 2027 Earnings Summary

• Revenue, Q1 2027 vs. Q1 2026: ¥129,495m vs. ¥108,002m (higher year on year)
• Net Income from Continuing Operations, Q1 2027 vs. Q1 2026: ¥16,997m vs. ¥11,206m (higher year on year)
• Basic EPS, Q1 2027 vs. Q1 2026: ¥39.02 vs. ¥28.21 (higher earnings per share year on year)
• Trailing Net Margin, latest 12 months vs. prior year: 23.7% vs. 4.5% (margin much stronger, helped by a ¥49.8b one off gain)

Prefer clean charts over another wall of earnings tables and ratios? See Sumitomo Pharma's full financial picture, including a clear view of its valuation and profitability trends, in the company report for Sumitomo Pharma.

Sumitomo Pharma bull case leans on core earnings

The bullish story around Sumitomo Pharma is that structural reform plus a focused urology and oncology portfolio is now driving resilient, higher quality earnings. Q1 FY2027 does support parts of that. Revenue of ¥129,495m and basic EPS of ¥39.02 sit on top of a trailing net margin of 23.7%, which lines up with management’s claim of tighter SG&A and R&D control and a move into a more profitable phase. Recent clinical milestones, including orphan drug status in both AML and ALL for enzomenib and full enrollment of the pivotal Phase 2 acute leukemia study, show the hematology pipeline is hitting the timelines management laid out. TWYMEEG revenue in Japan has passed the ¥10b annual run rate threshold, which activates better terms for a partner and suggests the metabolic portfolio is starting to add another recurring revenue pillar.

Bear case focuses on one offs and concentration risk

The bear view is that Sumitomo Pharma’s earnings lean too heavily on one time gains and a narrow North American product set that faces policy and pricing pressure. The trailing 23.7% net margin is explicitly helped by a ¥49.8b one off gain from the China and Asia business transfer. This supports the concern that current profitability overstates ongoing earnings power. Management also still calls out ORGOVYX and GEMTESA as primary growth engines and highlights FY2026 guidance that normalizes after those one offs. This fits the idea that core margins could compress as R&D steps up toward ¥51b and beyond. U.S. policy changes around out of pocket caps and IRA related negotiations are already flagged as headwinds to pricing flexibility, so regulatory and reimbursement risk remains very much live in the Sumitomo Pharma story.

Review whether Sumitomo Pharma's one off gains and earnings concentration are early warnings or outliers by scanning the independent risk analysis for Sumitomo Pharma which shows 3 important warning signs.

Stay Ahead With Simply Wall St

If Sumitomo Pharma's recent earnings strength and low P/E have your attention, register for free with Simply Wall St and add it to your Watchlist to track the share price against fair value and watch how the story develops. When you decide to take a position, keep on top of what matters using the Portfolio Command Center so you get focused updates instead of day to day noise. For a broader view on sentiment and ideas around Sumitomo Pharma and other stocks, use the Community to tap into real investor discussions. This way you spot potential catalysts and risks earlier and give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond Sumitomo Pharma?

Fresh ideas often move first, and slow research can get caught chasing momentum. Scan curated stocks that could be setting up for their next breakout while it matters and consider acting earlier in your process.

• Spot sturdy companies that can potentially handle shocks before the crowd by checking the curated 58 resilient stocks with low risk scores, which keeps financial resilience and downside control front and center.
• Evaluate potential cash flow and balance sheet strength while valuations still look reasonable by reviewing the hand picked list of solid balance sheet and fundamentals stocks (39 results), a tool that emphasizes substance over story.
• Position ahead of possible demand shifts in critical resources by reviewing the focused 29 best rare earth metal stocks, which highlights producers linked to long term tech and energy themes.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com